ArticleFrontiers in oncology2022

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.

Changchang Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.